Five Prime Therapeutics

Five Prime Therapeutics Newswire

Comprehensive Real-Time News Feed for Five Prime Therapeutics.

Results 1 - 20 of 183 in Five Prime Therapeutics

  1. Roche Says Swiss Franc's Surge May Erode Profit Growth This YearRead the original story

    41 min ago | The Washington Post

    Roche Holding AG, the world's largest seller of cancer drugs, said the Swiss franc's surge may strip 9 percentage points from growth in operating profit this year. The currency's strength will probably pare 6 percentage points from sales growth, based on the average exchange rate for January, Chief Financial Officer Alan Hippe said at a press conference in Basel today.

    Comment?

  2. Roche Sees Profit, Sales IncreasingRead the original story w/Photo

    5 hrs ago | Wall Street Journal

    Roche Holding AG posted a 16% drop in annual profit as the Swiss drug maker booked large impairments and restructured its debt, but the company said Wednesday it expects sales and profit to increase this year. Basel-based Roche said sales are expected to grow in low- to mid-single digits in 2015, when stripping out the effect of foreign-currency exchange rate fluctuations.

    Comment?

  3. Roche misses forecasts as costs riseRead the original story w/Photo

    6 hrs ago | MarketWatch

    Swiss drug maker Roche Holding AG said Wednesday that its full-year net income fell 16% despite rising sales of its cancer treatments. Basel-based Roche said net income attributable to shareholders fell to 9.33 billion Swiss francs from 11.16 billion francs a year earlier, missing analysts' forecasts of 11.54 billion francs.

    Comment?

  4. Roche Profit Misses ForecastsRead the original story w/Photo

    7 hrs ago | Wall Street Journal

    Swiss drug maker Roche Holding AG said Wednesday that its full-year net income fell 16% despite rising sales of its cancer treatments. Basel-based Roche said net income attributable to shareholders fell to 9.33 billion Swiss francs from 11.16 billion francs a year earlier, missing analysts' forecasts of 11.54 billion francs.

    Comment?

  5. Zeltiq Aesthetics Inc (ZLTQ), Five Prime Therapeutics Inc (FPRX): Point72's Latest Bullish MovesRead the original story w/Photo

    17 hrs ago | Insider Monkey

    Steve Cohen 's Point72 Asset Management has made bullish moves into a pair of medical technology stocks. According to separate filings with the SEC, the fund has obtained 5.2% and 5.0% stakes in Zeltiq Aesthetics Inc and Five Prime Therapeutics Inc , respectively.

    Comment?

  6. Justin Sullivan/Getty Images For a few holdouts, Mass. still isn't biotech centerRead the original story w/Photo

    Monday Jan 19 | Boston.com

    Genetech, headquartered in south San Francisco, does not plan to open a research and development facility in the Boston area. "We do deals with Boston companies.

    Comment?

  7. Jefferies Group Raises Five Prime Therapeutics Price Target to $32.00Read the original story

    Friday Jan 16 | AmericanBankingNews.com

    ... analysts have also recently issued reports about the stock. Analysts at Zacks upgraded shares of Five Prime Therapeutics from a "neutral" rating to an "outperform" rating and set a $29.50 price target on the stock in a research note on Tuesday. ...

    Comment?

  8. J.P. Morgan: Five Prime Therapeutics, Inc. CEO Says Experimental Drug ...Read the original story w/Photo

    Wednesday Jan 14 | BioSpace

    January 15, 2015 By Riley McDermid , BioSpace.com Breaking News Sr. Editor Clinical stage biotech Five Prime Therapeutics Inc intends to put its experimental drug FPA008 to work tackling six tumor types in clinical trials that combine it with Bristol-Myers Squibb 's Opdivo, its chief executive told audience members at the J.P. Morgan Healthcare Conference Thursday. That news initially pushed shares of the Bay Area biotech up in Thursday trading--more welcome news on a day when Five Prime saw its rating upgraded by several analysts and investor websites.

    Comment?

  9. Roche Holding acquiring majority stake in US firm Foundation MedicineRead the original story w/Photo

    Monday Jan 12 | Big News Network.com

    Our eNewspaper network was founded in 2002 to provide stand-alone digital news sites tailored for the most searched-for locations for news. With a traditional newspaper format, more than 100 sites were established each with a newspaper-type name to cover the highest-ranked regions, countries, cities and states.

    Comment?

  10. Roche invests $1B in U.S. genomics firmRead the original story w/Photo

    Monday Jan 12 | USA Today

    Shares of Foundation Medicine more than doubled in pre-market trading early Monday, when Roche Holding AG announced plans to purchase a majority stake in the Cambridge, Mass.-based genomics company. Roche said Roche invests $1B in U.S. genomics firm Shares of Foundation Medicine more than doubled in pre-market trading early Monday, when Roche Holding AG announced plans to purchase a majority stake in the Cambridge, Mass.-based genomics company.

    Comment?

  11. Roche to buy $1B stake in genomics companyRead the original story w/Photo

    Monday Jan 12 | Salt Lake Tribune

    San Francisco a Roche Holding plans to pay more than $1 billion for a majority stake in Foundation Medicine Inc. to get access to genomic tests for screening tumors and to develop a new generation of treatments for fighting cancer. Roche will buy 5 million new shares of Cambridge, Mass.-based Foundation for $50 each and make an offer to purchase stock from existing investors for the same price to take its stake to as much as 56 percent, the companies said in a statement Monday.

    Comment?

  12. Switzerland's Roche Holding and AC Immune strike U.S. dealsRead the original story w/Photo

    Monday Jan 12 | TheStreet.com

    Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

    Comment?

  13. Roche to buy majority stake in FoundationRead the original story w/Photo

    Monday Jan 12 | RTE.ie

    Roche Holding will acquire a majority stake in molecular and genomic analysis firm Foundation Medicine for up to $1.18 billion, it said today. This targeted approach to treating disease is gaining traction in many medical fields and is attractive to governments and insurers who pay for healthcare, since it means that drugs should go only to patients who are likely to benefit.

    Comment?

  14. Roche to buy majority stake in Foundation for up to $1.18ibnRead the original story w/Photo

    Monday Jan 12 | Independent.ie

    The logo of Swiss pharmaceutical company Roche is seen outside the Shanghai Roche Pharmaceutical Co. Ltd. headquarters in Shanghai May 22, 2014.

    Comment?

  15. REFILE-UPDATE 1-Roche to buy majority stake in Foundation for up to $1.18 blnRead the original story

    Sunday Jan 11 | Reuters

    Roche Holding will acquire a majority stake in molecular and genomic analysis firm Foundation Medicine Inc for up to $1.18 billion, it said on Monday, in a move to bolster the Swiss drugmaker's personalised cancer treatments. This targeted approach to treating disease is gaining traction in many medical fields and is attractive to governments and insurers who pay for healthcare, since it means that drugs should go only to patients who are likely to benefit.

    Comment?

  16. Drug company CEO's fountain dip signals born-again biopharma businessRead the original story w/Photo

    Friday Jan 9 | Business Journal

    ... week alone, Menlo Park's Avalanche Biotechnologies Inc. (NASDAQ: AAVL) and South San Francisco's Five Prime Therapeutics Inc. (NASDAQ: FPRX) - two of the 26 Bay Area life sciences IPOs in the past two years - returned to the market to raise a ...

    Comment?

  17. Five Prime Therapeutics, Inc. To Present At The 33rd Annual Healthcare ConferenceRead the original story

    Thursday Jan 8 | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer, will present at the 33rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 9:30 AM Pacific Standard Time. The conference will take place at the Westin St. Francis Hotel in San Francisco.

    Comment?

  18. Global Specialty Enzymes Market Size and Forecast Up to 2020 by Grand View ResearchRead the original story

    Thursday Jan 8 | PR.com

    Grand View Research has announced the addition of "Global Specialty Enzymes Market Analysis And Forecasts To 2020" Market Research report to their Database. San Francisco, CA, January 08, 2015 -- -- Positive outlook on global pharmaceutical industry is expected to remain a key driving factor for global specialty enzymes market.

    Comment?

  19. Cancer-fighting CytomX lands $20 million Pfizer investment, makes key hiresRead the original story w/Photo

    Tuesday Jan 6 | Business Journal

    ... disclosed Tuesday, comes after CytomX on Monday announced a trio of key hires, including former Five Prime Therapeutics chief scientific officer Dr. W. Michael Kavanaugh . South San Francisco's CytomX is developing what it calls "probodies," which ...

    Comment?

  20. CytomX Expands Leadership Team with Addition of Michael Kavanaugh,...Read the original story

    Monday Jan 5 | Freshnews

    ... Prior to joining CytomX, Dr. Kavanaugh was senior vice president and chief scientific officer of Five Prime Therapeutics. Since joining the company in 2009, he held multiple positions in research and development and led the growth of the company's ...

    Comment?